The chemical or enzymatic synthesis and modification of nucleos(t)ides is a major research topic in organic, medicinal, and bioorganic chemistry. This book contains a selection of different chapters prepared by highly reputed scientists involved in the field of nucleosides and nucleotides, covering different aspects of their synthesis and/or their applications that provide valuable information to all the scientists working in this field. Each chapter in this volume reflects the own work performed by the respective contributors in the laboratories.
The first seven chapters are involved with the enzymatic or chemoenzymatic synthesis of nucleic acid derivatives. Nowadays, the application of bioprocesses catalyzed by whole cells or enzymes in industrial settings is gaining momentum as compared to traditional chemical synthetic processes. In this context, the enzymatic synthesis of active pharmaceutical ingredients (APIs) shows many advantages, such as one-pot reactions under mild conditions, high stereo-and regioselectivity, and an environmentally friendly technology.
In this context, many different authors are working together to publish a special issue that will focus on the development of new enzymatic or chemoenzymatic strategies for the synthesis of nucleic acid derivatives catalyzed either by whole cells or enzymes, showing the advantages and drawbacks of this methodology versus traditional chemical methods
In the first chapter, Kamel et al. have performed an exhaustive revision about the potential of nucleoside phosphorylases (NPs) as biocatalysts for industrial synthesis of nucleoside analogues, providing detailed information about their substrate specificity and structural properties that influence their activity. Additionally, they describe the potential of mutagenic approaches to widen the substrate spectrum of nucleoside phosphorylases, showing an overview about the upscaling approaches for the production of nucleoside analogues
In Chapter 2, Dr. Daniela Ubiali and Prof. Giovanna Speranza present an overview of the recent work on enzymatic phosphorylation of nucleosides to nucleoside 5 ′ -monophosphate (NMPs) by nonspecific acid phosphatases In a different way, Dr. Eremeeva and Dr. Herdewijn, in Chapter 7, present an exhaustive revision about the enzymatic synthesis of redesigned nucleic acids (xeno-nucleic acids, XNA) using polymerases. In this sense, the enzymatic production of several XNAs, such as base-modified XNAs, sugar-modified XNAs, or the phosphodiester backbone-XNA, is reported.
The last five chapters concentrate on the chemical synthesis and/or applications of these unique molecules. Particularly, Chapters 8-12 deal with the chemical synthesis of nucleosides and oligonucleotides. Thus, in Chapter 8, Dr. Seley-Radke reports a historic perspective of the synthetic approaches followed for the preparation of a unique class of nucleosides, the fleximer nucleosides, designed to understand better how the flexibility in the nucleobase affects the receptor-ligand recognition and function and their potential to overcome the challenges of binding site mutations. Fleximers are flexible nucleosides with several key advantages over natural purine nucleosides.
Chapter 9 by Dr. Eritja et al. focuses on the synthesis of oligonucleotides bearing nucleic acid derivatives of biomedical and structural interest. In this chapter, an overview of valuable and versatile nucleic acid derivatives developed by the group during the past decade is presented together with their emerging applications as well as a highlight of the important recent progress made in the field.
In Chapter 10, Dr. Morales describes the synthesis and applications of carbohydrate-oligonucleotide conjugates. The interest in such conjugates is to take advantage by integrating the properties of both kinds of molecules (carbohydrates and oligonucleotides) in a single molecule. This type of conjugates have attracted a lot of attention to explore their application as potential therapeutic agents, aptamers, ribozymes, biosensors, biochips, diagnostic tools, etc.
Chapter 11 focuses on microarrays; Dr. Damha and colleagues detail the advances in light-directed synthesis of high-density microarrays. This interesting chapter gathers the phosphoramidite chemistry applied to the photolithographic synthesis of microarrays; the recent improvements in the synthesis of DNA microarrays; the synthesis of RNA microarrays; the enzymatic approaches to RNA array synthesis; and the synthesis of 2 ′ F-ANA microarrays. Finally, in Chapter 12, Dr. Schinazi and coworkers describe how SAMHD1 (a dNTP triphosphohydrolase that degrades dNTPs into 2 ′ -deoxynucleosides and triphosphates) mediates the negative regulation of cellular dNTP levels. We hope that the readers will find the contents of this book interesting and instructive and challenging enough to be involved in the fantastic field of nucleos(t)ides and nucleic acids. Finally, last but not the least, the editors sincerely thank all the authors who have contributed to this book with very interesting chapters. Nucleosides primarily consist of a nitrogenous base (nucleobase), which is either a purine base or a pyrimidine base and a five-carbon sugar (pentose). The base and sugar are covalently linked via an N-glycosidic bond (Figure 1 .1).
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The pentose sugar moiety of naturally occurring canonical nucleosides is either ribose or deoxy-ribose whereas the nucleobase might be either a purine (adenine, guanine) or a pyrimidine (cytosine, uracil, thymine). These nucleosides are structural subunits of nucleic acids and are involved in several cellular processes including enzyme regulation and metabolism, DNA and RNA synthesis, and cell signaling [1, 2] . Naturally occurring nucleoside analogues (non-canonical nucleosides) are found in almost all types of RNA especially in tRNAs and they are crucial for RNA processing. Non-canonical analogues are nucleosides with different modifications on the pentose and/or the base [3] (Figure 1.1 ). There are more than 109 known post-transcriptional modifications in the three phylogenetic domains [4] . Pseudouridine is the most ubiquitous analogue and is sometimes considered as the fifth RNA-related nucleoside [5] .
Non-natural nucleoside analogues are synthetic molecules that structurally mimic their physiological counterparts and also act as antimetabolites [2] . Nucleoside analogues access cells through specific nucleoside transporters. Within the cells, they are phosphorylated by nucleoside kinases, which leads to increased levels of di-and tri-phosphorylated nucleoside analogues in virus-infected or cancer cells. The first and the second phosphorylation step can also be catalyzed by viral kinases in cells infected by some DNA viruses. Owing to differences in the substrate spectrum of human and viral kinases, virus-specific drugs can be developed. The active forms of nucleoside analogues interfere with intracellular enzymes such as human and viral polymerases, kinases, DNA methyl transferase, ribonucleotide reductase, nucleoside phosphorylases (NPs) or thymidylate synthase [2, 6] . Furthermore, they can be incorporated into newly synthesized DNA and RNA, which may induce termination of the polymerization process, accumulation of mutations in viral progeny, or induction of apoptosis. For more than 50 years, nucleosides and their analogues have been used as small molecule drugs for the treatment of several viral infections as well as for hematological malignancies and solid tumors. The first FDA approved antiviral nucleoside analogue was idoxuridine, which is used for the treatment of HSV-1 (herpes simplex virus) [7] . In 1969, cytarabine was approved for the treatment of acute myeloid leukemia [2] . Since then, the interest in nucleoside analogues based drugs has tremendously grown. Currently, more than 39 approved nucleoside analogue drugs or drug combinations are approved for the treatment of seven human viral infections, which include HSV, varicella zoster virus (VZV), hepatitis-B virus (HBV), hepatitis-C virus (HCV), human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), and human cytomegalovirus (HCMV) [7] . For treatment of cancer and viral infections, 50% and 20%, respectively, of all approved drugs belong to the class of nucleoside analogues [8] . Additional clinical indications for nucleoside analogues application include chronic hyperuricemia, immune suppression in organ transplant surgeries, and autoimmune disease as well as chronic obstructive pulmonary disease and asthma [2] .
Emerging from the significance of nucleoside analogues, there have been continuous attempts to improve and simplify their synthesis processes. With the world moving toward green chemistry approaches, the enzymatic synthesis of nucleoside analogues offers several advantages over chemical methods, which include higher total yields, a higher regio-and stereo-selectivity, and higher product purity. This allows for more biological and clinical trials [9] . Accordingly, enzymatic strategies are considered as a step forward to a more efficient synthesis of nucleosides and their analogues.
Enzymes Involved in the Enzymatic Synthesis of Nucleoside Analogues
Two main classes are employed in the enzymatic synthesis of nucleosides and their analogues: NPs and N-deoxyribosyltransferases (NDTs). In this chapter, the focus is on enzymatic approaches using NPs. NPs are of high interest as biocatalysts because of their wide substrate spectrum and abundance in almost all living organisms.
Nucleoside Phosphorylases
NPs are enzymes belonging to the transferases family (EC 2.4 and EC 2.7.7). NPs catalyze the reversible phosphorolysis of nucleosides into their respective nucleobase and pentofuranose-1-phosphate (Pentose-1P). NPs have been extensively studied since 1911 when Levene and Medigrecenau [10, 11] , and Johnes [10-13] observed the enzymatic hydrolysis of nucleosides. Later, Levene et al. isolated an enzyme (nucleosidase) from cattle's spleen, kidney, and pancreas, which catalyzed the hydrolysis of both inosine and adenosine in phosphate buffer, yielding a base and a ribose moiety [14] [15] [16] . In 1947, Kalckar demonstrated that the formed ribose was in fact ribose-1-phosphate and that the isolated enzyme was a purine nucleoside phosphorylase (PNP) [17] . Later, it was proven that Escherichia coli cells and cell extracts thereof contained enzymes that could phosphorolyze thymidine to thymine and deoxyribose-1-phosphate [18].
Classification and Substrate Spectra of Nucleoside Phosphorylases
Nucleoside phosphorylases are classified based either on their substrate specificity/affinity (Table 1 .1) or on their structure [19] . In 2002, Pugmire and Ealick described a structure-based classification of NPs in two distinct families [19, 20] : NP-I and NP-II (Figure 1 .2). They demonstrated that members of an NP-I family share the following characteristics [20] : (i) they have a single domain subunit, (ii) they share a common α/β-subunit fold, (iii) their quaternary structure is either trimeric (mammals/higher organisms) or hexameric (bacteria/lower organisms), (iv) they accept both purine nucleosides (bacterial and mammalian PNPs) and pyrimidine nucleosides (uridine phosphorylase, UP) as substrates, and (v) their substrate-binding sites are similarly arranged. Nevertheless, they are quite different in their quaternary structures, amino acid sequence, and substrate specificity. Additionally, active sites of the hexameric family members are significantly different from those of the trimeric enzymes of higher eukaryotes, which makes them attractive targets for the specific treatment of bacterial or parasitic infections. Members of the NP-II family are characterized by (i) having two domain subunits: a small α-domain and a large α/β-domain separated by a large cleft, (ii) a dimeric quaternary structure, (iii) being specific to pyrimidine nucleosides, (iv) accepting both thymidine and uridine as substrates in case of lower organisms, and thymidine in higher organisms' members of the family, (v) having more than 30% sequence similarity, and (vi) undergoing high conformational changes and domain movements during catalysis.
Nucleoside Phosphorylase-I Family
Members of the NP-I family are subdivided into PNP, uridine nucleoside phosphorylase and 5 ′ -deoxy-5 ′ -methythioadenoside phosphorylase (MTAP) (Figure 1 .2). They catalyze reversible phosphorolysis of the N-glycosidic bond of purines, uridine, and 5 ′ -deoxy-5 ′ -methythioadenoside (MTA), respectively. PNPs are the most widely studied group of nucleoside phosphorylases due to their importance as drug targets.
Purine Nucleoside Phosphorylases (PNPs) PNPs are further classified into two main groups, trimeric PNPs and hexameric PNPs (Figure 1.2) . Trimeric PNPs also named as low molecular mass PNPs (approx. 31 kDa per subunit) are specific for 6-oxopurines (guanine and hypoxanthine) and their nucleosides. The hexameric PNPs (also known as high molecular mass PNPs) consist of subunits with a size of approximately 26 kDa [20] and have a broader substrate spectrum. They accept both, 6-oxopurines and 6-aminopurines (adenine) and their nucleosides. Initially, trimeric forms were described to be specific for mammals and hexameric forms for bacteria. However, later it was shown that E. coli, Bacillus subtilis, and Bacillus stearothermophilus possess both forms [20] [21] [22] [23] [24] .
Several reports showed that PNPs accept a wide range of substrate, thereby showing the wide substrate spectrum of these enzymes. Generally, the substrate spectrum of hexameric PNPs is larger than that of the trimeric ones [19] . As it will be mentioned in detail later, modifications on the nucleobase and the sugar moiety highly influence the substrate recognition by the enzyme, and both the binding to and releasing from the active sites (Figure 1.2) .
PNPs mostly recognize and cleave the N9-C1 ′ glycosidic bond of purines. However, bonds between N3-C1 ′ and N7-C1 ′ are cleaved as well by PNPs from different origins including E. coli and bovine and human PNPs [25] [26] [27] . Base substitutions with electronegative groups (thiol, halogen, and thioalkyl) at C6 and small alkyl substitution at N7 are well accepted by some members of the PNP family (Figure 1.2) . Unexpectedly, open ring purine nucleoside analogues (as ribavirin) bearing structure similarities to inosine were found to be cleaved by some PNPs from various organisms including E. coli, B. subtilis, Brevibacterium acetylicum, calf, and human [27] [28] [29] .
Maintaining the electronegativity at C1 ′ is crucial for substrate recognition by PNPs. Hence, ribo-and arabinonucleosides are well accepted by PNPs of E. coli and a number of thermostable PNPs [30] [31] [32] . The loss of 2 ′ -OH and or 3 ′ -OH reduced the phosphorylation efficiency of human PNP. The replacement of 3 ′ -OH by an amino group improved the activity compared to 3 ′ -deoxy-nucleosides due to the retained electronegativity [33] . Nonetheless, there are some exceptions that also accept 3 ′ -deoxynucleosides, such as PNPs isolated from B. acetylicum, Plasmodium carotovorum, and Geobacillus thermoglucosidasius [30, 34, 35 ].
An interesting feature of PNPs is their ability to accept pyrimidine nucleosides as substrate. Thus, they may be interesting catalysts for the synthesis of cytidine and deoxycytidine that are not utilized by many pyrimidine nucleoside phosphorylases (PyNPs) [30] .
5
′ -Deoxy-5
′ -methylthioadenoside Phosphorylase (MTAP) An interesting member of the NP-I family is MTAP, which was primarily characterized in rats to work on MTA. MTAPs show a wide substrate spectrum. In addition to MTA some MTAPs as those isolated from Pyrococcus furiosus and Sulfolobus solfataricus accept 6-oxopurine nucleosides (guanosine and inosine). For these enzymes, higher sequence similarities to PNPs compared to the known MTAPs were shown [36] [37] [38] . Substitutions with halogen or amino groups at the C2 position of the purine ring are very well tolerated [39] [40] [41] [42] [43] (Figure 1.2) . MTAP isolated from Aeropyrum pernix has some unique characteristics: on one hand, it is active toward some pyrimidines including cytidine and deoxycytidine, and on the other hand, unlike most reported MTAPs, it phosphorolyzes 2 ′ -fluoro-modified arabinoside [30] , which is an interesting activity when considering the enzymatic synthesis of nucleoside analogues that can be used as drugs.
Uridine Nucleoside Phosphorylase Different prokaryotic and eukaryotic organisms including E. coli, Lactobacillus casei, Enterobacter aerogenes, Salmonella typhimurium, Saccharomyces cerevisiae, Schistosoma mansoni, Mus musculus, Rattus norvegicus, and Homo sapiens were reported to possess a UP [19] .
Although UPs of different origins vary in their substrate spectrum, they show some common features: none of the reported UPs catalyze cytidine phosphorolysis except the UP from S. cerevisiae. However, all accept 2 ′ -deoxy nucleosides, although with much lower affinity compared to uridine. Nucleosides that are halogenated or methylated at the C5 position are generally well accepted and tolerated [19] (Figure 1 .2).
Nucleoside Phosphorylase-II Family
The NP-II family comprises phosphorylases that catalyze the reversible cleavage of the glycosidic bond of thymidine (thymidine phosphorylase [TP] ) and pyrimidines (PyNPs) in the presence of phosphate. Although UP catalyzes a similar reaction, it has been classified under the NP-I family due to its distinct structural features. As mentioned earlier, both TP and PyNP share two-domain subunits with a high percentage (≈40%) of sequence and structural similarities [19, 20, 44] . However, one major catalytic difference between TP and PyNP exists: TP has a high specificity toward C2
′ deoxy nucleosides compared to PyNPs [45] . Hence, PyNPs possess a wider substrate spectrum than TP.
Thymidine Phosphorylase Structure-function relationship studies have provided some insight into the acceptance of base and sugar modifications by TP. Regarding the sugar moiety, the absence of a hydroxyl group (-OH) at the C2 ′ position of the nucleoside is crucial for TP binding. Both, E. coli and human TP, do not accept uridine as a substrate. In fact, uridine and 2 ′ -methyl uridine were shown to inhibit the catalytic action of E. coli TP [46] [47] [48] [49] . On the other hand, the presence of the 3 ′ -OH group of the nucleoside is crucial for interactions between the substrate and the enzyme. This is reinforced by the fact that 3 ′ -amino-3 ′ -deoxythymidine was phosphorolyzed by TP only at pH 8 and not at pH 6.5, because at pH 6.5 both the 3 ′ -amino group of the nucleoside and the amino group of the enzyme are positively charged [48] . The 5 ′ -position of the nucleoside does not strongly influence the catalytic reaction. Various 5 ′ modifications were tolerated by E. coli TP including halogens, thio, amino, and deoxy substitutions [48] [49] [50] (Figure 1.2) . Modifications in the C5 position of the base are generally well tolerated by TP, while substitutions at C6 have a big impact on the catalytic potential. Substitutions that increase the aromaticity of the nucleobase hinder the base to leave the catalytic pocket of the enzyme [49] .
Pyrimidine Nucleoside Phosphorylases PyNPs have been isolated and characterized from several organisms including B. stearothermophilus, B. subtilis, G. thermoglucosidasius, Thermus thermophilus, Hameophilus influenza, and
Mycoplasma hyorhinis [45, [51] [52] [53] [54] [55] . PyNPs are of increasing interest due to their broader substrate affinity and tolerability compared to those of TP or UP. Thus, a wider application of these enzymes to produce synthetic nucleoside analogues is envisioned.
PyNPs well tolerate modification at the C5 position of the base. PyNPs from various organisms are able to catalyze the glyosidic bond cleavage of 2 ′ -deoxy-5-halogenated nucleoside analogues (Figure 1.2) . Additionally, a bromovinyl (CH=CHBr) group at C5 was tolerated by E. coli TP and B. subtilis PyNP. Several other modifications at C5 including alkyl groups are also well accepted by PyNPs from various sources [45, [56] [57] [58] (Figure 1.2) . Interestingly, compounds with modifications at the C2 ′ position of the nucleoside are also accepted as substrates by PyNPs. Arabinosides as well as 2 ′ -deoxy-2 ′ -fluororibosides and 2 ′ -deoxy-2 ′ -fluoroarabinosides are substrates for some PyNPs, predominantly for those isolated from thermophilic organisms such as T. thermophilus [54] (Figure 1 .2).
Limitations in the Current Classification
Although the classification of PNPs into two main categories as proposed by Pugmire and Ealick [20] is applicable for most of the known PNPs, there are still some exceptions that do not fit into this categories.
The low molecular mass inosine-guanosine phosphorylase extracted from the vegetative state and the spores of Bacillus cereus was shown to either have a tetrameric quaternary structure or to equilibrate between the dimeric and the tetrameric form [24] . B. stearothermophilus (JTS-859 strain) as mentioned earlier contains both forms of PNPs: a low molecular mass and a high molecular mass PNP. It was reported that the low molecular mass enzyme forms a dimer rather than a trimer whereas the high molecular mass form is a tetramer rather than a hexamer [24] .
E. coli hexameric PNP-II (product of xapA gene) has an amino acid sequence, promotor structure, and substrate specificity similar to the low molecular mass PNPs. As observed for low molecular mass PNPs, E. coli PNP-II does not accept adenosine or adenosine derivatives as substrates [19, 24, 59 ].
Reaction Mechanism
Nucleoside phosphorylases reversibly cleave N-glycosidic bonds of β-nucleosides with configurational inversion producing α-pentofuranose-1-phosphate and a free nucleobase. The catalytic mechanism of the phosphorolytic cleavage has been reported for several members of the NP-I family. Most of the reported NPs were shown to have a similar catalytic mechanism (Figure 1.3) . NP-II members are expected to follow the same pattern.
The mechanism described for human PNP illustrated that the general reaction follows an S N 1 mechanism [20, 60] . The nucleoside binds to the enzyme in a high energy conformation producing a steric strain on the glycosidic bond, thus favoring bond cleavage. An oxocarbenium ion is formed during the transition state by the flow of an electron from O4 ′ to the purine base rendering the base with a negative charge. The formed oxocarbenium ion is stabilized by phosphate ions. Additionally, negative charges on the base moiety are stabilized by interactions of the enzymes active site to the N-atom of the base, thus facilitating glycosidic bond cleavage [19, 20, 60, 61] .
The mechanism of phosphorolytic cleavage became clear by the availability of crystal structures; however, the exact mechanism of nucleoside synthesis is still not clear and difficult to elaborate due to the difficulty of crystallizing pentose-1-phospahte alone with PNP. Yet, it is suggested that the presence of the 
Nucleoside Phosphorylases 9
base favors the binding of pentose-1-phosphate to the catalytic site. Otherwise, the latter would cause steric hindrance of base binding [24, 60, 61] .
PNP reactions follow non-Michaelis Menten kinetics. However, an exact kinetic mechanistic model was not agreed upon so far [24, 60] . Crystal structure data suggest the formation of ternary complexes of enzyme/nucleoside/ phosphate and enzyme/base/pentose-1-phosphate. Whether these complexes are formed in a sequentially defined order or by random binding was not yet confirmed. Nevertheless, while there is no evidence for the occurrence of a ping-pong mechanism, a sequential order of the reaction is assumed by most authors [24].
Domain Structure and Active Site Residues of Nucleoside Phosphorylases

NP-I Family Members
As mentioned earlier, members of the NP-I family share a single domain structure that is highly conserved [62] . Nevertheless, amino acid residues in the active sites are not necessarily conserved among different members of the NP-I family.
One interesting difference between the four subgroups (trimeric PNP, MTAP, hexameric PNP, and UP) of the NP-I family is the observed sequence motifs. Although sequence motifs do not necessarily reflect functional differences, they help to show differences and similarities between subgroups of enzymes. There are nine identified sequence motifs in NP-I family (Figure 1.4) . These structural regions are denoted with letters A-I. Their exact position in the primary amino acid sequence was reviewed by Pugmire and Ealick in 2002 [20] . Numbering codes were assigned based on structure similarities, for example B 1 , and B 2 are similar regarding their quaternary structure's position; however, their amino acid sequence differs significantly. Not all members of the subclasses have the same number of motifs, but all of them encompass motif A 1 . Noteworthy, MTAP (E 3 , H 2 ) and UP (H 3 , I 1 ) have two unique motifs that are involved in the active site and inter-subunit interactions [20] .
From nine motifs identified in the members of the NP-I family, seven are involved in the formation of the active site and six are involved in subunit interaction. The observed structural similarities between trimeric PNP and MTAP as well as between hexameric PNP and UP are also reflected in the motif structure (Figure 1.4) . Amino acid residues involved in binding of phosphate, nucleobase, and pentose sugar differ between hexameric and trimeric members of the NP-I family [19, 20] . Detailed information on amino acids involved in substrate binding has been recently reviewed [19] .
Functionally, the four subclasses of the NP-I family showed different specificities toward substrates. Trimeric PNPs are specific to 6-oxopurines and MTAPs are described to be specific for 5 ′ deoxy-5 ′ -methylthioadenosinde, whereas hexameric PNPs accept both 6-oxopurines and 6-aminopurines (adenosine). UP is strictly specific to pyrimidine derivatives with no distinct specificity toward the C2 ′ position. These functional divergences are also reflected by differences in the amino acid residues found in the active sites. hMTAP (Asp220) and E. coli PNP (Asp204) form hydrogen bonds with the 6-amino group of the purine base. The replacement of an aspartic acid residue (Asp) with asparagine (Asn) as in the case of human and bovine PNP (Asn243) restricted the activity of human and bovine PNP toward 6-oxopurines (Figure 1 .5). As another example, E. coli and human UP are conserved in residues Gln166, Arg168, and Arg223, which are described to be responsible for the specificity of UP [19] .
NP-II Family Members
TP and PyNP are the main two enzyme groups within the NP-II family. Enzymes from both classes share a high degree of sequence similarity (33-67%). Furthermore, they share two main domain subunits, a large α/β domain and a smaller α domain, that are separated from each other by a large cleft. The amino acid residues of the α domain are more conserved. Detailed information on amino acids involved in substrate binding has been recently summarized [19] .
Active site residues are highly conserved among TP and PyNP with few exceptions that might be responsible for differences in substrate acceptance. While TP is highly specific for 2 ′ -deoxy nucleosides, PyNP catalyzes the cleavage of a number of 2 ′ -modified nucleosides. A possible explanation that is revealed by structural studies is the substitution of lysine (Lys108) of PyNP with methionine in both E. coli and human TP [19] . This replacement alters the
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hydrogen bonding organization between the 2 ′ -hydroxyl group of the nucleoside and the oxygen atom of the phosphate. An alternative explanation is a different positioning of 2 ′ -modified nucleosides in the active site of TP compared to 2 ′ -deoxy nucleosides [63].
Enzymatic Approaches to Produce Nucleoside Analogues Using Nucleoside Phosphorylases
Despite the huge advances achieved in the chemical synthesis of nucleosides and their analogues, the existing drawbacks led to a continuous interest in developing enzymatic approaches. In 1954, M. Friedkin and D. Roberts [64, 65] reported the first attempts to enzymatically synthesize pyrimidine nucleoside analogues using TP isolated from horse liver. Since then several studies have been conducted on enzymes to be used in the synthesis of nucleoside analogues. As mentioned earlier, nucleoside phosphorylases catalyze the reversible cleavage of N-glycosidic bond of nucleosides. Thus, the condensation of a nucleobase and pentose-1-phosphate can be used for the synthesis of nucleosides or their analogues. Different synthesis strategies were developed based on this mechanism of action.
One-pot Two-Step Transglycosylation Reaction
Enzymatic transglycosylation has been extensively studied [9, 66, 67] . It is the transfer of a pentofuranose moiety from a chemically synthesized or a naturally occurring nucleoside to a base of interest. Pentose-1P is formed as an intermediate in the reaction (Figure 1.6a) . Sugar donor is a pyrimidine nucleoside (cleavage reaction) and sugar acceptor is a purine base (synthesis reaction) or vice versa. This reaction takes place in the presence of phosphate. As noted earlier, reactions catalyzed by NPs are reversible, thus both cleavage and synthesis take place simultaneously and the reaction applies to equilibrium rules and dynamics that might hinder high product yields.
In case of producing a purine nucleoside via transglycosylation, it is generally assumed that the reaction equilibrium is on the side of the starting nucleoside and that the reaction of the PyNP is faster compared to the PNP due to the modifications in the purine base. In other words, in a transglycosylation reaction the formed intermediate (Pentose-1P) may easily undergo the backward reaction to the starting nucleoside than to the final product. High phosphate concentration enhances nucleoside cleavage [19] , but hinders the synthesis of the nucleoside of interest. Therefore, adjusting the phosphate concentration in transglycosylation reactions is a critical factor. Although the transglycosylation reaction was proven to be an efficient way for the synthesis of mainly riboside and deoxy-ribosides nucleoside analogues, the synthesis of some arabinosides and fluoro-modified-ribosides/arabinosides is more challenging [66] [67] [68] . Hence, further enzymatic approaches were investigated. The chemical synthesis of glycosyl phosphates has a long history and has been thoroughly studied and reported [69] [70] [71] [72] [73] . Although details of the chemical synthesis will not be discussed in this chapter, it is worth mentioning that the most efficient and currently used method for the synthesis of pyranose-1-phosphate is that proposed by MacDonald in 1962 [70] . Later, this method was also used for the production of α-d-pentofuranose-1-phosphate (Pentose-1P) [68, 74] . Tediousness of the chemical synthesis of Pentose-1P as well as low yields, and the difficulty of purifying the wanted α-anomeric isoform have so far restricted the use of Pentose-1P as a substrate for NPs; generally, the availability of Pentose-1P is a serious bottleneck for the synthesis of modified nucleoside analogues. Nevertheless, the chemical synthesis of Pentose-1P followed by the enzymatic condensation with a nucleobase using NPs is still considered as a valuable chemo-enzymatic route for nucleoside synthesis.
Nucleosides Synthesis from D-Glyceraldehyde-3-phosphate
2
′ -deoxyribonucleoside synthesis from glyceraldehyde-3-phosphate was first reported as a potential enzymatic approach for nucleoside synthesis in the beginning of this century [75, 76] . The authors described the transformation of d-glyceraldehyde-3-phosphate or dihydroxyacetone monophosphate to nucleoside analogues through three main consecutive steps. The transformation was performed as a one-pot reaction without purification of the intermediates. In the first step, a condensation of d-glyceraldehyde-3-phosphate or dihydroxyacetone-phosphate with acetaldehyde is catalyzed by d-2-deoxyribose-5-phosphate aldolase (DERA) and triose phosphate isomerase (TRI). The observed product is d-ribofuranose-5-phosphate. In the second step the stereospecific transformation of d-ribofuranose-5-phosphate into α-d-ribofuranose-1-phosphate (Rib-1P) by phosphopentomutase (PPM) is performed. Finally, the enzymatic condensation of Rib-1P with a heterocyclic nucleobase is catalyzed by NPs (Figure 1.6b(I) ).
Nucleoside Synthesis from D-Pentose
In 2008 The formed pentofuranose-5-phosphate (Pentose-5P) was transformed into Pentose-1P using PPM. Pentose-1P was then used by nucleoside phosphorylase for the enzymatic condensation reaction with nucleobase yielding nucleosides and their analogues (Figure 1.6b(II) ). Inosine, 6-mercaptopurine riboside and ribavirin were successfully synthesized by the above method [77] .
More recently [78] , a different and more efficient strategy was proposed based on transforming d-pentose to Pentose-5P using ribokinase (RK). Pentose-5P was later converted to Pentose-1P by PPM. Pentose-1P was used as a substrate for NP to synthesize nucleoside analogues in the presence of heterocyclic nucleobases like uracil, thymine, and hypoxanthine ( Figure 1.6b(III) ).
Nucleoside Synthesis from Enzymatically Produced Pentose-1P
We have recently proposed a two-pot enzymatic approach to produce nucleoside analogues as an alternative to the one-pot transglycosylation [79] . This approach is based on the ability of nucleoside phosphorylase to cleave the glycosidic bond of nucleoside yielding Pentose-1P, which is then purified as barium salt. It is applied in a separate step as a substrate for the synthesis of modified nucleosides using NPs (Figure 1.6a) . This approach allows for easier optimization of each of the reactions, which leads to increased yields of the desired nucleoside analogue.
Approaches to Produce Nucleoside Analogues
Since nucleoside phosphorylases were first described by Kalckar [80] , many research projects were conducted to test whether definite nucleoside analogues are used as substrates for nucleoside phosphorylases. Different forms of the enzyme (e.g. free or immobilized) were applied for the production of known drugs. One common objective of various studies was the optimization of already existing methods for large-scale industrial production with the aim to overcome some drawbacks and limitations such as (i) product inhibition, (ii) poor solubility of substrates, and/or (iii) consumption of large amounts of enzymes that might be hard to express. Such scale-up activities focused mainly on compounds with biological activity or of commercial value. In the coming sections, we try to summarize these approaches.
Whole Cell Catalysis
The application of whole cells can be regarded as an easy, time-saving, and economic option to produce nucleoside analogues. Expensive and time-consuming steps like cells lysis, enzyme extraction, and purification are avoided. Additionally, the retrieval and reuse of cells via centrifugation or ultrafiltration is possible. Best yields and conversion rates were achieved by cells harvested at the stationary phase where the salvage pathway for nucleoside production is strongly activated, which correlate with large amounts of nucleoside phosphorylases [81] . Ribavirin, dideoxyinosine, adenine arabinoside, and 2 ′ -amino-2 ′ -deoxyadenosine were synthesized using whole cells and different pentofuranosyl donors [81] [82] [83] [84] [85] [86] . One requirement for the successful application of whole cell biocatalysts is that both the sugar donor and acceptor are well soluble. Using whole cell catalysts, side reactions that are catalyzed by other enzymes acting on the same class of substrates have to be considered, for example deaminases or lipases [87, 88] .
Complex media were proven to be better than defined media for producing NPs in Enterobacter species [89] . Many nucleobases, nucleosides, Rib-1P, and nucleotide monophosphates as inducing agents for potentiating the expression of NPs were tested. Conversion by some eukaryotic cancer cell lines was also reported [90, 91] .
Another biologically important molecule is benzimidazole, whose nucleoside exhibits antitumor, antifungal, antiparasitic, analgesics, antiviral, and antihistamine activities, and is being used in the treatment of cardiovascular diseases and in therapies related to neurology, endocrinology, and ophthalmology. Bentancor and coworkers [92] published a screening study for producing benzimidazole riboside and 2 ′ -deoxyriboside using whole cells catalysts. Uridine was applied as a ribose donor and thymidine as the 2 ′ -deoxyribose donor, respectively. Optimal temperature for the reaction was 60 ∘ C for ribosides and 45 ∘ C for deoxyribosides, respectively, suggesting that the higher temperature inhibits the action of thymidine phosphorylase [93, 94] . However, recent data show that α-deoxyribose-1-phosphate is unstable and degrades at higher temperature [95] .
Mainly, free cells were applied to produce nucleoside analogues, but immobilized cells were also used. Immobilized whole cells can be either alive or dead depending on (i) whether the enzyme is intra-or extracellular, (ii) the molecular weight and the size of the enzyme, (iii) substrate and product, and (iv) the cell's permeability to them. As an example, Aeromonas hydrophila cells were entrapped in agarose beads and afforded the same kinetics and yields as those by the free cells. The entrapped cells, however, were used three times before any decrease in activity was detected [81] . A mutant strain of E. coli was cross-linked to glutaraldehyde and successfully used to produce ribavirin and the anticancer drug cladribine [96] .
The widespread application of whole cell extracts is restricted because broadly used bacterial whole cells that are used as biocatalysts for the production of modified nucleosides co-express a number of enzymes that can (i) consume substrates; (ii) catalyze undesired transformations of substrates or formed nucleosides; and (iii) secrete desired products in the medium, which makes purification challenging [97].
Crude Enzyme Extract
Compared to purified enzyme, the application of crude cell extract is a less laborious and a more economical approach. It is suitable to carry out preliminary screening assays to determine the catalytic potential of enzymes especially in the cases of overexpression where the target enzyme is available in high concentration. A drawback of crude enzyme extracts is a shorter half-life compared to that of purified enzymes [53, 56, 82, [98] [99] [100] .
The application of crude enzyme extracts is principally advantageous in case of thermophilic enzymes. If the enzymes are heterologously expressed in a recombinant host, proteolysis and interference from the host proteins can be inhibited through an additional heat shock step [101] . This was implemented in the preliminary tests conducted for the characterization of nucleoside phosphorylases of T. thermophilus. The extract was heated at 80 ∘ C for one hour and then centrifuged. Afterward, the supernatant was successfully tested for its phosphorolysis activity with a variety of nucleosides [31] .
As compared to whole cell catalysis, cell lysate or enzyme extracts result in a more reproducible and robust reaction as the Pentose-1P intermediate is not consumed as an energy source, which might happen under certain conditions using bacterial cells. It can finally end up with the reaction being totally reserved in the backward direction [102].
Application of Purified Enzymes
The use of purified enzyme preparations has the advantage that side-reactions are avoided. To date, NPs from different mesophiles, like E. coli [103] [104] [105] or B. subtilis [106] , were applied in the synthesis of pharmacologically active compounds [103, 104] .
Thermostable NPs from thermophilic or hyperthermophilic microorganisms catalyze enzymatic reactions with the same high regio-and stereo-selectivity compared to mesophilic NPs, but have several advantages for large-scale applications: (i) thermophilic enzymes can be easily purified with high protein recovery after heterologous production and costs are low as a heat treatment usually is sufficient as a purification step [31] ; (ii) a high pH tolerance is observed, which reduces the need to finely regulate the pH of the reaction; (iii) it was shown that PNPs of T. thermophilus show a remarkable resistance to aggressive organic solvents such as dimethylformamide or dimethyl sulfoxide, which are required in the synthesis of compounds with low water solubility; (iv) using thermophilic catalysts, reactions can be performed at elevated temperatures, which are frequently required to reduce the viscosity of the medium or to increase the solubility and concentration of some substrates [107] ; (v) it was observed that an increased thermal stability correlates with a broader substrate spectrum [30, 31, 54, 108] .
For industrial applications of purified enzymes, it is highly desirable to use either immobilized catalysts or continuous reactors to be able to recover the enzyme from the reaction mixture. This simplifies downstream processing and facilitates biocatalyst recycling. As immobilization might also increase the stability of nucleoside phosphorylases, diverse methods have been exploited [57, 101, 109, 110] . Approaches for both immobilized enzymes and continuous reactors are described in more detail in the following paragraphs.
Immobilized Enzymes
Biocatalyst immobilization denotes binding an enzyme to an inert support (natural, synthetic, or inorganic in nature) where it maintains its activity without blocking or disrupting the active sites. The ideal support has to be stable, endures sheering force of the reaction, can be regenerated, and has no effect on the type of reaction [111, 112] . Usually, enzyme immobilization has a positive effect regarding thermal stability, pH resistance, and longevity (e.g. storage time and number of operational cycles).
Immobilization of purified enzymes is an important tool for large-scale commercial application of biocatalysts. Considering the cost load of the enzyme in the reaction, one economically favorable feature is the ability to reuse the enzyme as long as it retains its activity. The general immobilization principles for enzymes are (i) adsorption to the support's surface, (ii) cross-linking (enzyme molecules bind to each other) in the presence of spacers (e.g. polyethylene glycol) to reduce steric hindrance, (iii) covalent binding to a support, (iv) entrapment within a polymer, (v) encapsulation within a surrounding matrix, and (vi) affinity binding [113, 114] (Figure 1.7) . The most described immobilization method for NPs is entrapment in different matrices like agar, agarose, and alginates [81, 86, 116] .
Immobilization of pure enzyme to produce nucleoside analogues in a transglycosylation reaction might be a complicated process as it involves the co-binding of a PNP and PyNP. Multimeric enzymes are known to be quite difficult to immobilize as it is necessary to consider the correct assembly and multisubunit attachment, least desorption, and minimal deactivation [117] [118] [119] . However, feasibility was proven as immobilized PyNPs from B. subtilis and TP from E. coli were applied for the synthesis of 5-halogenated-pyrimidine-2 ′ -deoxyribonucleosides by transglycosylation in fully aqueous medium [57] . For both enzymes, immobilization was shown to strongly enhance the stability upon incubation in acetonitrile. Both PyNP and TP could be re-used for at least five times with no loss of productivity. In another approach, immobilized UP of Clostridium perfringens and PNP of A. hydrophila were used as biocatalysts for the production of vidarabine in a transglycosylation reaction [120] . Different matrices and techniques were compared by Rocchietti and coworkers for UP and PNP from B. subtilis [117] . While covalent bonding distorted the protein structure and resulted in decreased activity and stability, UP was best immobilized via ionic bonding to Sepabeads and post-immobilization treatment with polyaldehyde was necessary to cross-link the support and protein. PNP was best immobilized on glycoxyl-agarose using the surfactant Triton X-100 that prevents agglomeration of the protein and hence, allows diffusion into the support. The combined use of these two enzymes allowed the reaction to take place at a higher optimal temperature (45 ∘ C) and pH (pH = 10) compared to the free enzymes. Using these conditions, guanine conversion proceeded, which is usually limited due to low solubility.
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Enzyme Reactors
Few trials were recorded in literature using different NPs in enzyme reactors for the production of nucleoside analogues. Preparative scale nucleoside synthesis was conducted in column reactors by some research groups. Hori and colleagues operated their experiment for 17 days at 60 ∘ C to produce 5-methyl uridine from a thymine and inosine mixture [101] . Immobilized crude enzyme extract from the thermophilic bacterium B. stearothermophilus was bound to an ion-exchange column. The reaction mixture was fed in a pre-optimized rate with the aim to overcome the equilibrium constant and to guarantee that the hypoxanthine solubility limit is not exceeded [101] .
In two other approaches an enzyme column reactor was connected to a HPLC [121, 122] . The purified PNP from A. hydrophila was immobilized on silica particles of definite particle size. The system could run over the analytical column or bypass it via a six-port switching valve and it was used to test the substrate affinity of the enzyme and compare the reaction kinetics of free and immobilized enzyme [121] . Later it was shown that the system was stable for 10 months [122] .
